Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDT Company Better Therapeutics Ready To Go Public With SPAC Deal

Executive Summary

Better Therapeutics is developing prescription digital therapeutics for behavioral therapy to address the root causes of cardiometabolic disease.

You may also be interested in...



Pear Therapeutics Obtains First Medicaid Coverage For PDTs

Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.

Exec Chat: Pear Therapeutics’ CEO Charts Future For Digital Therapeutics Following SPAC Deal

Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.

Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022

The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel